BCG
Bacillus Calmette-Guerin (BCG) is a live vaccine against tuberculosis (8). It should not be given to immunocompromised individuals and those on immunosuppressant’s and biologics e.g. rituximab - Read comprehensive list in chapter 6 in the Green Book.
All pre-transplant patients require a mantoux test to check their BCG status. Patients with a negative mantoux will require the BCG vaccine. Tuberculin testing should not be carried out within 4 weeks of receiving a MMR vaccine as the response may be a falsely negative. If the mantoux test has already been initiated, then MMR should be delayed until it has been read unless protection against measles is urgent. (see Appendix IV)
Dosage schedule for BCG vaccine by intradermal injection:
Age < 12 months – a single dose 0.05ml
Age ≥ 12 months - single dose 0.1ml
No further immunisations should be given in the arm used for BCG for at least three months, due to risk of regional lymphadenitis.
Patients cannot be listed on the Transplant List for at least 3 month following BCG vaccine.
NB for patients treated at the Royal Hospital for Children in Glasgow, the mantoux +/- BCG are performed in ward 1C. At present this can be requested on Trakcare.
Hepatitis B
(NB Different manufacturer products may NOT always be interchangeable. Always check)
Hepatitis B containing vaccines are inactivated (not live): they do not contain live organisms and cannot cause the diseases against which they protect.
All children born on or after 1 August 2017 will have received hepatitis B as part of the routine childhood immunisation programme. Therefore children born on or after this date who require haemodialysis (HD), peritoneal dialysis (PD) and renal transplantation, will only require annual antibody levels - with a booster dose given if required, see table below for recommendations.
All ESRF, dialysis and pre-transplant children born up to and including 31 July 2017 will need to be vaccinated against hepatitis B.
Dosage schedule by Intramuscular* injection ESRF, pre-transplant HD and PD:
Age
|
Vaccine
|
Dose
|
1month – 15years
|
Engerix B®
|
10micrograms given at month 0, 1, 2
(accelerated schedule).
Booster dose at 12 months. (2)
|
16 – 17years
|
Engerix B®
|
40micrograms given at month 0, 1, 2
(accelerated schedule).
Booster dose at 6 months. (2)
|
Antibody levels are checked 2-3 months after the final dose, see table below for recommendations. For dialysis patients these are monitored annually. If they fall below 100iu/L (or below 100mIU/ml) a booster dose should be given to patients who have previously responded to the vaccine.
Anti-HBs antibody titre
|
Response
|
Recommendation
|
100iu/L
|
Protective
|
Give booster dose at 5 years
|
10 - 100iu/L
|
Poor responder
|
Give booster at 1 & 5 years
|
<10iu/L
|
Non-responder
|
Repeat course of vaccine
|
*Deltoid muscle is preferred in older children; anterolateral thigh is preferred site in neonates, infants and young children; not to be injected into the buttock (vaccine efficacy reduced).
MMR
MMR (measles, mumps and rubella) is a live vaccine. It should not be given to immunocompromised individuals (see section 8). All pre-transplant patients require a MMR vaccine as part of their childhood vaccines. The second MMR can be given at 18 months of age (as long as interval of at least 3 months after the first vaccine) if the child is in ESRF/CKD stage 5 and will be active on the transplant list before their pre-school vaccines.
MMR vaccine can be given from six months of age, for example during a local outbreak or if travelling to a high incidence country. Any dose of MMR given below the age of one year should be discounted as residual maternal antibodies may reduce the response to the vaccine. Two further doses of MMR will therefore be required at the appropriate ages.
Children <4years with eGFR <30ml/min/1.73m² consider bringing their pre-school booster forward.
If a child is over 10 years old and missed their primary vaccine schedule then the two MMR vaccines can be given 1 month apart.
All children with NS who have their childhood vaccination schedule interrupted due to high dose steroids or other immunosuppressant should have their second MMR as soon as possible. MMR vaccine can be given when high dose steroids have been discontinued for at least 3 months or on low dose steroids for at least 3 months (see Appendix II). Occasionally, individuals on lower doses of steroids may be immunosuppressed and at increased risk from infections. In those cases, live vaccines should be considered with caution, in discussion with their consultant. For all other immunosuppressant’s and biologics e.g. rituximab - Read comprehensive list in chapter 6 in the Green Book.
MMR is a live vaccine and the recommendations about timing when it can be given with other live vaccines has changed, see Appendix IV for guidance when giving at the same time as varicella vaccine and the montoux test.
Check measles antibody response 2-4 weeks after completing MMR course. If seroconversion is not confirmed a third dose may need to be given.
Patients cannot be listed on the Transplant List for at least 1 month following MMR vaccine.
Pneumococcal Polysaccharide Vaccine (PPV)
PPV containing vaccines are inactivated (not live): they do not contain live organisms and cannot cause the diseases against which they protect.
Pneumococcal polysaccharide vaccine (Pneumovax II) contains purified capsular polysaccharide from each of 23 capsular types of pneumococcus. All children with chronic kidney disease over 2 years of age will need a single dose of PPV to provide protection against the serotypes of S. Pneumoniae not covered by the primary immunisation course with Pneumococcal conjugate vaccine (PCV). All children should have completed as PCV13 (Prevenar®) as part of their routine childhood immunisation programme. However PCV is also available as PCV15 (Vaxneuvance®).
Children younger than two years of age show poor antibody responses to immunisation with PPV and therefore it is not suitable for this age group.
Dosage schedule by intramuscular*injection:
Age >2 years: A single dose of 0.5ml of PPV
*PPV are routinely given into the upper arm in children and adults or the anterolateral thigh in infants under one year of age unless they have a bleeding disorder then see Green Book.
Varicella Vaccine
Varicella vaccine is a live vaccine. It should not be given to immunocompromised individuals (see section 8).
All pre-transplant patients who are varicella zoster virus (VZV) IgG negative on testing will be given the varicella vaccine.
Ensure lymphocyte count >1.2-109/L
Delay for 3 months if patient has received immunoglobulins or blood transfusion.
Salicylates should be avoided for 6 weeks after vaccine.
All children with NS who are VZV IgG negative on testing will be given the varicella vaccine when high dose steroids have been discontinued for at least 3 months or on low dose steroids for at least 3 months (see Appendix II). Occasionally, individuals on lower doses of steroids may be immunosuppressed and at increased risk from infections. In those cases, live vaccines should be considered with caution, in discussion with their consultant. For all other immunosuppressant’s and biologics e.g. rituximab - Read comprehensive list in chapter 6 in the Green Book.
Varicella is a live vaccine and the recommendations about timing when it can be given with other live vaccines has changed, see Appendix IV for guidance when giving at the same time as MMR.
Dosage schedule for Varilrix® by deep subcutaneous or intramuscular injection:
Age > 1 year - two doses of 0.5ml, 4-8 weeks apart (not less than four weeks apart.)
Patients cannot be listed on the Transplant List for at least 1 month following varicella vaccine if seroconversion demonstrated, however Infectious Disease Consultants in the RHC do not recommend testing for seroconversion as immunity is assumed when 2 doses given. ELISA is not always sensitive enough to pick up vaccine induced immunity.
Influenza Vaccine
From September 2013 a new live Intranasal Influenza Vaccine was introduced to the Childhood Vaccine Schedule for all 2-11 year olds and since 2021 it is now recommended for all children from 2 years until they leave high school. It should not be given to immunocompromised individuals (see section 8) and children active on the Transplant list.
This vaccination is given yearly at planned Immunisation Clinics for all 2 years old to pre-school children and at school for all school children.
Inactivated Influenza Injection Vaccine
Seasonal influenza injection vaccine is an inactivated (not live) vaccine and should be given yearly to all children over 6 months with chronic kidney failure, CKD stages 3, 4 or 5, nephrotic syndrome and kidney transplantation.
Influenza Intranasal Vaccine
There is a LIVE intranasal influenza vaccine that should be avoided in all immunocompromised individuals (see section 8) and children active on the Transplant list. For all immunosuppressant’s and biologics e.g. rituximab - Read comprehensive list in chapter 6 in the Green Book.
COVID-19 Vaccine
COVID-19 vaccine is inactivated (not live). Vaccination advice and dosing recommendation is dependent upon the age of the child and the risk of severe COVID-19. See the most up to date advice in chapter 14a Green Book for all dosing and vaccination recommendations.
Human papillomavirus (HPV) Vaccine
HPV is recognised as a necessary cause of cervical cancer and is causally associated with less common cancers at other sites, including cancer of the vulva, vagina, penis and anus, and some cancers of the head and neck. HPV vaccine was first introduced to the vaccination programme in 2008 and offered to adolescent girls then in September 2019 was extended to include adolescent boys.
JCVI issued interim advice to move to a one-dose HPV schedule in February 2021. In June 2022 confirmed its advice and a statement confirming this advice was published in July 2022 advising the following schedules:
- a one-dose schedule for the routine adolescent programme
- a three-dose schedule for individuals who are immunosuppressed
The Electronic Medicines Compendium (EMC) for Gardasil® 9 states that the HPV indicated for active immunisation of individuals from the age of 9 years.